T1	p 326 339	breast cancer
T2	p 480 520	receiving chemotherapy for breast cancer
T3	p 827 875	chemotherapy-na?ve patients with breast cancer .
T4	p 1106 1170	8 . Median age of the 94 women was 51 years ( range 27-76 ) : 79
T5	p 1180 1220	fluorouracil/epirubicin/cyclophosphamide
T6	p 1225 1227	15
T7	p 1237 1295	doxorubicin/cyclophosphamide . Thirteen withdrew pre-cycle
T8	i 32 50	placebo-controlled
T9	i 115 128	dexamethasone
T10	i 151 172	adjuvant chemotherapy
T11	i 543 567	dexamethasone or placebo
T12	i 757 782	oral dexamethasone ( 4 mg
T13	i 806 822	) versus placebo
T14	i 910 977	granisetron and dexamethasone pre-chemotherapy and oral granisetron
T15	i 1237 1267	doxorubicin/cyclophosphamide .
T16	i 1384 1391	placebo
T17	i 1467 1480	dexamethasone
T18	i 1676 1689	dexamethasone
T19	i 1862 1886	dexamethasone or placebo
T20	i 1902 1923	adjuvant chemotherapy
T21	o 85 92	quality
T22	o 96 100	life
T23	o 274 280	nausea
T24	o 285 293	vomiting
T25	o 592 625	delayed nausea and vomiting , and
T26	o 629 660	compare quality of life ( QOL )
T27	o 1018 1047	) patient preference ; ( ii )
T28	o 1084 1090	of QOL
T29	o 1535 1598	intensity of vomiting , nausea , or time to onset of vomiting .
T30	o 1626 1641	in global QOL (
T31	o 1695 1720	other symptom/QOL domains
T32	o 1809 1839	preference , QOL , or symptoms